Rapid drug susceptibility testing with a molecular beacon assay is associated with earlier diagnosis and treatment of multidrug-resistant tuberculosis in California

Journal of Clinical Microbiology

Volumn 48, Issue 10, 2010, Pages 3779-3781

  Banerjee, Ritu ^a   Allen, Jennifer ^b   Lin, S Y Grace ^b   Westenhouse, Janice ^b   Desmond, Ed ^b   Schecter, Gisela F ^b   Scott, Cheryl ^b   Raftery, Ann ^c   Mase, Sundari ^d   Watt, James P ^b   Flood, Jennifer ^b  

^a MAYO CLINIC   (United States)

^b CALIFORNIA DEPARTMENT OF PUBLIC HEALTH   (United States)

^c Francis J Curry National Tuberculosis Center   (United States)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; CAPREOMYCIN; CYCLOSERINE; ETHIONAMIDE; ISONIAZID; KANAMYCIN; LINEZOLID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG SENSITIVITY; EARLY DIAGNOSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MOLECULAR BEACON; MULTIDRUG RESISTANT TUBERCULOSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; UNITED STATES;

ADULT; ANTITUBERCULAR AGENTS; CALIFORNIA; EARLY DIAGNOSIS; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; MYCOBACTERIUM TUBERCULOSIS; RETROSPECTIVE STUDIES; TIME FACTORS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 77957760079     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.01236-10     Document Type: Article

References (10)

1. Centers for Disease Control and Prevention. 2006. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs - worldwide, 2000-2004. MMWR Morb. Mortal. Wkly. Rep. 55:301-305.
2. Centers for Disease Control and Prevention. 2009. Report of expert consultations on rapid molecular testing to detect drug-resistant tuberculosis in the United States. Centers for Disease Control and Prevention, Atlanta, GA. http://www.cdc.gov/tb/topic/laboratory/rapidmoleculartesting/MolDSTreport.pdf.
3. Cooksey, R. C., G. P. Morlock, S. Glickman, and J. T. Crawford. 1997. Evaluation of a line probe assay kit for characterization of rpoB mutations in rifampin-resistant Mycobacterium tuberculosis isolates from New York City. J. Clin. Microbiol. 35:1281-1283.
4. Greenaway, C., D. Menzies, A. Fanning, R. Grewal, L. Yuan, J. M. Fitzgerald, and the Canadian Collaborative Group in Nosocomial Transmission of Tuberculosis. 2002. Delay in diagnosis among hospitalized patients with active tuberculosis - predictors and outcomes. Am. J. Respir. Crit. Care 165:927-933.
5. Lin, S. Y. G., W. Probert, M. Lo, and E. Desmond. 2004. Rapid detection of isoniazid and rifampin resistance mutations in Mycobacterium tuberculosis complex form cultures or smear-positive sputa by use of molecular beacons. J. Clin. Microbiol. 42:4204-4208.
6. Phoa, L.-L., M. D. Teleman, Y.-T. Wang, and C. B. E. Chee. 2005. Characteristics of patients with delayed diagnosis of infectious pulmonary tuberculosis. Respirology 10:196-200.
7. Piatek, A. S., S. Tyagi, A. C. Pol, A. Telenti, L. P. Miller, F. R. Kramer, and D. Alland. 1998. Molecular beacon sequence analysis for detecting drug resistance in Mycobacterium tuberculosis. Nat. Biotech. 16:359-363.
8. Wallace, R. M., J. S. Kammerer, M. F. Iademarco, S. P. Althomsons, C. A. Winston, and T. R. Navin. 2009. Increasing proportions of advanced pulmonary tuberculosis reported in the United States: are delays in diagnosis on the rise? Am. J. Respir. Crit. Care 180:1016-1022.
9. World Health Organization. 2008. Molecular line probe assays for rapid screening of patients at risk of multi-drug resistant tuberculosis (MDR-TB). World Health Organization, Geneva, Switzerland. http://www.who.int/tb/features- archive/expert-group-report-june08.pdf.
10. World Health Organization. 2006. Guidelines for the programmatic management of drug-resistant tuberculosis. WHO/HTM/TB/2006.361. World Health Organization, Geneva, Switzerland.